Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81-8973 from rFVIII-FS can continue their dosing schedule with improved protection.

Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2020)

Keyphrases